Investigating how certain enzymes affect bladder cancer mutations
Official title: The Mutagenic Effects of APOBEC3A and APOBEC3B in Urothelial Carcinoma
Funded at Univ of North Carolina Chapel Hill · NIH-10825932 · Data updated 2026-11-12
This study is looking at how two specific enzymes might cause changes in bladder cancer, which could help explain why some tumors grow faster and resist treatment, and it's designed for people interested in understanding more about their cancer and potential therapies.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2027 |
| Funding year | 2024 |
| Award (this year) | $35,843 |
| NIH project number | 1F31CA281339-01A1 |
| Project ID | NIH-10825932 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with urothelial carcinoma, particularly those with advanced or metastatic disease.
✕Less likely to help
Patients with non-urothelial types of bladder cancer or those without active disease may not benefit from this research.
What this research studies
This research focuses on understanding the role of two enzymes, APOBEC3A and APOBEC3B, in causing mutations in urothelial carcinoma, the most common type of bladder cancer. By studying how these enzymes contribute to tumor evolution and treatment resistance, the research aims to clarify their individual impacts on cancer progression. The approach involves using mouse bladder cancer cell lines to observe the mutagenic effects of these enzymes and their influence on the tumor's response to immune therapies. This could provide insights into why some tumors are more aggressive and resistant to treatment.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for bladder cancer by identifying specific targets for therapy.
How similar studies have gone: Previous research has shown that targeting mutagenic processes in cancer can lead to significant advancements in treatment, suggesting this approach may yield valuable insights.
Where this research is happening
-
Univ of North Carolina Chapel Hill
Chapel Hill, United States Active
Researchers
- Principal investigator: Sturdivant, Michael Sean — Univ of North Carolina Chapel Hill
- Study coordinator: Sturdivant, Michael Sean
Related research
Other NIH-funded projects on the same topics.
-
Understanding bladder cancer biology to find new biomarkers and therapies
A study at Tuskegee University will look at the molecules inside high-grade bladder cancer to discover new markers and potential treatment targets.
-
Improved 3D guidance for kidney-sparing endoscopic UTUC treatment
A Vanderbilt team is testing a new 3D-guided approach to precisely locate and treat upper tract urothelial cancer during kidney-sparing endoscopic procedures.
-
Immune cells in bladder cancer: predicting who benefits from stronger pre-surgery therapy
This grant aims to find immune clues in muscle-invasive bladder cancer to identify which patients will best respond to intensified pre-surgery treatment.
-
Synergistic immune boost for bladder cancer with EphrinB2 blocker and PD-1 therapy
A phase II trial tests whether a new EphrinB2 blocker (sEphB4-HSA) plus pembrolizumab can help patients with muscle-invasive bladder cancer who have EphrinB2 and low Nectin4 to fight their cancer.
-
HER2 PET scans to find HER2 differences and predict response to HER2-targeted therapy in bladder cancer
This project uses a PET scan that lights up HER2 to help show which people with metastatic bladder (urothelial) cancer might benefit from HER2-targeted antibody-drug conjugates.
-
Treating bladder cancer with ARID1A gene changes
This project will develop new treatment approaches for people with bladder cancer whose tumors have changes in the ARID1A gene.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.